Renerve (ASX:RNV) signed an agreement with information technology services provider NetCentrix Ventures to pursue regulatory approval for its nerve cuff product NervAlign in India, according to a Thursday filing with the Australian bourse.
Under the deal, NetCentrix will assist ReNerve with testing, validation, and regulatory approvals through its Indian government partnerships, the filing said.
Shares of the company rose 10% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.